Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Antiviral Activity of IDX184 with Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Chronic Hepatitis C
2011-001878-25Phase 2Completed
- Sponsor
- Idenix Pharmaceuticals
- Start
- Nov 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Hepatitis C genotype 1 comparing IDX184 combination arm with Standard of care arm (2 arms). Primary endpoint: Safety and tolerability (adverse events). Started Nov 2011; status: completed.
02
Drugs
IDX184
03
Conditions
Hepatitis C genotype 1
Beyond the preview
Go deeper on 2011-001878-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001878-25.